A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/ Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

Cherry Creek Medical Center
University of Colorado Hospital

Principal Investigator
Photograph of Virginia Borges

Virginia Borges

Study ID

Protocol Number: 21-3077

More information available at ClinicalTrials.gov: NCT04862663

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers